株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

心房細動:パイプライン製品の分析

Atrial Fibrillation - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232800
出版日 ページ情報 英文 97 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
心房細動:パイプライン製品の分析 Atrial Fibrillation - Pipeline Review, H2 2016
出版日: 2016年08月10日 ページ情報: 英文 97 Pages
概要

心房細動とは、心拍数が不規則に(また往々にして急速に)なるという疾患で、人体内部の血流を停滞させる原因となっています。主な症状として、血圧低下や脱力感、軽い頭痛、意識混濁、胸痛などが挙げられます。疾病素質には、年齢や心臓病、高血圧、家族歴、飲酒などがあります。薬物治療・外科手術などが主な治療法となっています。

当レポートでは、世界各国での心房細動治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

心房細動の概要

治療薬の開発

  • 心房細動向けパイプライン製品:概要
  • 心房細動向けパイプライン製品:比較分析

各企業で開発中の心房細動治療薬

大学/研究機関で研究中の心房細動治療薬

心房細動治療薬:パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

心房細動治療薬:開発中の製品の一覧(企業別)

心房細動治療薬:研究中の製品の一覧(大学/研究機関別)

心房細動治療薬の開発に従事している企業

  • ARCA biopharma, Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • Cardiome Pharma Corp.
  • 第一三共
  • Dong-A Socio Holdings Co. Ltd.
  • Gilead Sciences, Inc.
  • Laboratoires Pierre Fabre SA
  • 日産化学工業
  • OMEICOS Therapeutics GmbH
  • 大塚ホールディングス
  • Xention Limited

心房細動:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

心房細動治療薬:開発が休止状態の製品

心房細動治療薬:開発が中止された製品

心房細動関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8335IDB

Summary

Global Markets Direct's, 'Atrial Fibrillation - Pipeline Review, H2 2016', provides an overview of the Atrial Fibrillation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atrial Fibrillation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Atrial Fibrillation
  • The report reviews pipeline therapeutics for Atrial Fibrillation by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Atrial Fibrillation therapeutics and enlists all their major and minor projects
  • The report assesses Atrial Fibrillation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Atrial Fibrillation

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Atrial Fibrillation
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Atrial Fibrillation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Atrial Fibrillation Overview
  • Therapeutics Development
    • Pipeline Products for Atrial Fibrillation - Overview
    • Pipeline Products for Atrial Fibrillation - Comparative Analysis
  • Atrial Fibrillation - Therapeutics under Development by Companies
  • Atrial Fibrillation - Therapeutics under Investigation by Universities/Institutes
  • Atrial Fibrillation - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Atrial Fibrillation - Products under Development by Companies
  • Atrial Fibrillation - Products under Investigation by Universities/Institutes
  • Atrial Fibrillation - Companies Involved in Therapeutics Development
    • ARCA biopharma, Inc.
    • AstraZeneca Plc
    • Bristol-Myers Squibb Company
    • Cardiome Pharma Corp.
    • Daiichi Sankyo Company, Limited
    • Dong-A Socio Holdings Co. Ltd.
    • Gilead Sciences, Inc.
    • Laboratoires Pierre Fabre SA
    • Nissan Chemical Industries, Ltd.
    • OMEICOS Therapeutics GmbH
    • Otsuka Holdings Co., Ltd.
    • Xention Limited
  • Atrial Fibrillation - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AFC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-919373 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bucindolol hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • edoxaban tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • F-373280 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • flecainide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Atrial Fibrillation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-967 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NIP-151 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMT-28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OPC-108459 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block Calcium-Activated Potassium Channel for Atrial Fibrillation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block GIRK for Atrial Fibrillation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block Voltage Gated Sodium Channel for Atrial Fibrillation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STP-023725 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vernakalant hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XEN-R0702 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XEND-0103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XENR-0703 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XENR-0706 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Atrial Fibrillation - Dormant Projects
  • Atrial Fibrillation - Discontinued Products
  • Atrial Fibrillation - Product Development Milestones
    • Featured News & Press Releases
      • May 11, 2016: Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study
      • May 02, 2016: New drug more effective in treating atrial fibrillation
      • Mar 31, 2016: Cardiome Announces Publication of Independent Study Comparing BRINAVESS to IBUTILIDE in Patients with Recent-Onset Atrial Fibrillation
      • Mar 24, 2016: Daiichi Sankyo to Present Findings From New Subgroup Analyses of Once-Daily SAVAYSA(edoxaban) in NVAF and VTE at ACC's 65th Annual Scientific Session
      • Jan 27, 2016: Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA
      • Jan 13, 2016: Cardiome announces filing of marketing authorization application for intravenous vernakalant in the Kingdom Of Saudi Arabia
      • Dec 22, 2015: Cardiome Files New Drug Submission Seeking Canadian Approval Of Intravenous Vernakalant
      • Nov 02, 2015: Daiichi Sankyo, Inc. Announces New Subgroup Analyses of Once-Daily SAVAYSA in Patients with Non-Valvular Atrial Fibrillation Will Be Presented at AHA Scientific Sessions 2015
      • Nov 02, 2015: OMEICOS Receives BMBF Research Grant to Advance its Novel Approach to Treat Atrial Fibrillation
      • Sep 23, 2015: UK's NICE recommends once-daily LIXIANA (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation
      • Aug 10, 2015: United Kingdom Department of Health Sets BRINAVESS Pricing
      • Jul 24, 2015: Cardiome Partner Eddingpharm to Initiate BRINAVESS Phase I Study in China
      • Jul 09, 2015: New Therapy to Help Heart Rhythm Patients Means Doctors are "Spoilt for Choice"
      • Jun 25, 2015: Daiichi Sankyo's Once-Daily LIXIANA (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE
      • Jun 12, 2015: Independent Study Finds Intravenous Vernakalant Facilitates Electrical Cardioversion in Patients with Cardioversion Resistant Atrial Fibrillation
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Atrial Fibrillation, H2 2016
  • Number of Products under Development for Atrial Fibrillation - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Atrial Fibrillation - Pipeline by ARCA biopharma, Inc., H2 2016
  • Atrial Fibrillation - Pipeline by AstraZeneca Plc, H2 2016
  • Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Atrial Fibrillation - Pipeline by Cardiome Pharma Corp., H2 2016
  • Atrial Fibrillation - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Atrial Fibrillation - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016
  • Atrial Fibrillation - Pipeline by Gilead Sciences, Inc., H2 2016
  • Atrial Fibrillation - Pipeline by Laboratoires Pierre Fabre SA, H2 2016
  • Atrial Fibrillation - Pipeline by Nissan Chemical Industries, Ltd., H2 2016
  • Atrial Fibrillation - Pipeline by OMEICOS Therapeutics GmbH, H2 2016
  • Atrial Fibrillation - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Atrial Fibrillation - Pipeline by Xention Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Atrial Fibrillation - Dormant Projects, H2 2016
  • Atrial Fibrillation - Dormant Projects (Contd..1), H2 2016
  • Atrial Fibrillation - Dormant Projects (Contd..2), H2 2016
  • Atrial Fibrillation - Dormant Projects (Contd..3), H2 2016
  • Atrial Fibrillation - Dormant Projects (Contd..4), H2 2016
  • Atrial Fibrillation - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Atrial Fibrillation, H2 2016
  • Number of Products under Development for Atrial Fibrillation - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top